![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KAT2A |
Gene summary for KAT2A |
![]() |
Gene information | Species | Human | Gene symbol | KAT2A | Gene ID | 2648 |
Gene name | lysine acetyltransferase 2A | |
Gene Alias | GCN5 | |
Cytomap | 17q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q92830 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2648 | KAT2A | LZE7T | Human | Esophagus | ESCC | 1.36e-07 | 3.03e-01 | 0.0667 |
2648 | KAT2A | LZE8T | Human | Esophagus | ESCC | 4.27e-02 | 9.18e-02 | 0.067 |
2648 | KAT2A | LZE22T | Human | Esophagus | ESCC | 3.22e-03 | 4.02e-01 | 0.068 |
2648 | KAT2A | LZE24T | Human | Esophagus | ESCC | 2.70e-15 | 4.03e-01 | 0.0596 |
2648 | KAT2A | P1T-E | Human | Esophagus | ESCC | 2.46e-14 | 7.62e-01 | 0.0875 |
2648 | KAT2A | P2T-E | Human | Esophagus | ESCC | 4.02e-22 | 3.49e-01 | 0.1177 |
2648 | KAT2A | P4T-E | Human | Esophagus | ESCC | 7.89e-08 | 2.76e-01 | 0.1323 |
2648 | KAT2A | P5T-E | Human | Esophagus | ESCC | 3.98e-23 | 2.47e-01 | 0.1327 |
2648 | KAT2A | P8T-E | Human | Esophagus | ESCC | 2.74e-16 | 2.37e-01 | 0.0889 |
2648 | KAT2A | P9T-E | Human | Esophagus | ESCC | 5.49e-10 | 2.14e-01 | 0.1131 |
2648 | KAT2A | P10T-E | Human | Esophagus | ESCC | 1.82e-16 | 2.53e-01 | 0.116 |
2648 | KAT2A | P11T-E | Human | Esophagus | ESCC | 3.78e-15 | 4.38e-01 | 0.1426 |
2648 | KAT2A | P12T-E | Human | Esophagus | ESCC | 5.89e-24 | 4.67e-01 | 0.1122 |
2648 | KAT2A | P15T-E | Human | Esophagus | ESCC | 2.82e-16 | 3.94e-01 | 0.1149 |
2648 | KAT2A | P16T-E | Human | Esophagus | ESCC | 5.73e-19 | 3.42e-01 | 0.1153 |
2648 | KAT2A | P17T-E | Human | Esophagus | ESCC | 1.59e-04 | 3.09e-01 | 0.1278 |
2648 | KAT2A | P19T-E | Human | Esophagus | ESCC | 3.14e-02 | 2.18e-01 | 0.1662 |
2648 | KAT2A | P20T-E | Human | Esophagus | ESCC | 5.66e-17 | 3.42e-01 | 0.1124 |
2648 | KAT2A | P21T-E | Human | Esophagus | ESCC | 2.69e-11 | 2.26e-01 | 0.1617 |
2648 | KAT2A | P22T-E | Human | Esophagus | ESCC | 1.73e-25 | 3.50e-01 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
GO:000184115 | Esophagus | ESCC | neural tube formation | 75/8552 | 102/18723 | 9.68e-09 | 1.95e-07 | 75 |
GO:000184314 | Esophagus | ESCC | neural tube closure | 66/8552 | 88/18723 | 1.98e-08 | 3.82e-07 | 66 |
GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
GO:001402014 | Esophagus | ESCC | primary neural tube formation | 69/8552 | 94/18723 | 4.22e-08 | 7.76e-07 | 69 |
GO:006060614 | Esophagus | ESCC | tube closure | 66/8552 | 89/18723 | 4.24e-08 | 7.76e-07 | 66 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa032502 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa0491912 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0325011 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa0491913 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KAT2A | SNV | Missense_Mutation | novel | c.1240N>T | p.Gly414Cys | p.G414C | Q92830 | protein_coding | tolerated(0.06) | possibly_damaging(0.687) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KAT2A | SNV | Missense_Mutation | rs782570663 | c.1627G>A | p.Val543Ile | p.V543I | Q92830 | protein_coding | tolerated(0.06) | benign(0.054) | TCGA-60-2709-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KAT2A | SNV | Missense_Mutation | novel | c.1016N>C | p.Val339Ala | p.V339A | Q92830 | protein_coding | tolerated(0.79) | benign(0.001) | TCGA-98-A53I-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | navelbine | SD |
KAT2A | SNV | Missense_Mutation | novel | c.544N>G | p.Leu182Val | p.L182V | Q92830 | protein_coding | deleterious(0.03) | probably_damaging(0.934) | TCGA-NC-A5HI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
KAT2A | SNV | Missense_Mutation | novel | c.1843N>A | p.Asp615Asn | p.D615N | Q92830 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-MT-A67A-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KAT2A | SNV | Missense_Mutation | novel | c.1544N>T | p.Arg515Leu | p.R515L | Q92830 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-G9-6377-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
KAT2A | SNV | Missense_Mutation | novel | c.2437N>A | p.Glu813Lys | p.E813K | Q92830 | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
KAT2A | SNV | Missense_Mutation | c.398N>A | p.Arg133His | p.R133H | Q92830 | protein_coding | tolerated(0.17) | probably_damaging(0.91) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |
KAT2A | SNV | Missense_Mutation | c.967C>T | p.Arg323Trp | p.R323W | Q92830 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
KAT2A | SNV | Missense_Mutation | novel | c.1968N>A | p.Asn656Lys | p.N656K | Q92830 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | PD-146176 | CHEMBL180917 | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | BEXAROTENE | BEXAROTENE | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | REVERSETRIIODOTHYRONINE | REVERSETRIIODOTHYRONINE | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | OCTADEC-17-YNOIC ACID | CHEMBL182310 | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | ANAZOLENE | ANAZOLENE | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | SIMAZINE | SIMAZINE | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | 5,8,11,14-EICOSATETRAYNOIC ACID | CHEMBL458328 | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | LINOLENIC ACID | LINOLENIC ACID | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | GAMOLENIC ACID | GAMOLENIC ACID | ||
2648 | KAT2A | TUMOR SUPPRESSOR, ENZYME | PURPURIN | PURPURIN |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |